EPZM - EPZM STOCK NEWS

Ipsen S.A. has extended the expiration date for its tender offer to acquire Epizyme, Inc. shares to August 11, 2022. The offer values Epizyme shares at $1.45 each, plus a contingent value right potentially worth up to $1.00. This extension allows additional time for compliance with the Hart-Scott-Rodino Antitrust Improvements Act. As of August 4, 2022, approximately 42.3 million shares—around 25% of Epizyme's outstanding shares—have been tendered. Stockholders are encouraged to accept the offer, and previously tendered shares do not need to be re-submitted.

Ipsen announced the acquisition of Epizyme for an all-cash tender offer at $1.45 per share, plus a contingent value right of $1.00 per share. The deal, unanimously approved by both boards, aims to enhance Ipsen's oncology portfolio by focusing on Tazverik^®, an EZH2 inhibitor approved for treating specific types of lymphoma. Ipsen anticipates that the acquisition will strengthen its market presence in oncology, despite expected moderate dilution in core operating income until the end of 2024.

Ipsen announced a definitive merger agreement to acquire Epizyme, focusing on Tazverik® (tazemetostat), an EZH2a inhibitor approved in the U.S. The acquisition involves an all-cash tender offer of $1.45 per share and a contingent value right (CVR) of $1.00 per share. Anticipating closure by Q3 2022, this deal enhances Ipsen’s oncology portfolio, aiming for increased sales and leveraging existing infrastructure. The transaction is expected to be moderately dilutive to Ipsen’s core operating income until 2024. Royalty Pharma, holding 20.5% of Epizyme shares, supports the acquisition.

Epizyme, Inc. (EPZM) announced updated safety and efficacy data from the ongoing Phase 1b study evaluating tazemetostat in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma (R/R FL). The interim analysis included 44 patients, showing a 95% objective response rate (ORR)—50% achieving complete response (CR). In a subgroup of rituximab-refractory patients, the ORR was 100%. The Phase 3 study will enroll approximately 500 patients. Tazemetostat was well tolerated with consistent safety profiles reported.

Epizyme (NASDAQ: EPZM) announced that CEO Grant Bogle and Senior Medical Advisor Shefali Agarwal will present at the H.C. Wainwright Global Investment Conference.

A pre-recorded fireside chat will be available at 7:00 AM EST on May 24, 2022, accessible via the investor section of www.epizyme.com and archived for 60 days.

Epizyme is dedicated to developing transformative therapies for cancer patients through innovative epigenetic approaches.

Epizyme reported first quarter 2022 financial results, highlighting net product revenue of $8.7 million, a 14% increase year-over-year. This includes $8.1 million in commercial net sales, marking a 10% rise from Q4 2021. Operating expenses decreased by 17% to $59.6 million, attributed to ongoing cost-efficiency measures. The company dosed the first patient in the Phase 3 SYMPHONY-1 study and anticipates presenting updated data at ASCO. The cash position stands at $199.7 million as of March 31, 2022.

Epizyme (NASDAQ: EPZM) is set to host a conference call on May 10, 2022, at 8:30 a.m. ET, to discuss its first quarter financial results and provide a business update. Investors can participate by calling (877) 844-6886 for domestic or (970) 315-0315 for international inquiries, using conference ID 5369344. A live webcast will also be available on the company's website and archived for 60 days afterward. Epizyme focuses on developing innovative cancer therapies that leverage novel epigenetic targets.

Epizyme (NASDAQ: EPZM) announced equity awards for COO Jerald Korn, effective April 1, 2022, as part of his employment agreement. Korn received options for 800,000 shares at an exercise price of $1.14 per share, matching the stock's closing price on the grant date. The options will vest incrementally, with 25% vesting on the first anniversary and the remainder monthly over the next three years, contingent on continued employment. These awards are approved under Nasdaq Listing Rule 5635(c)(4).

Epizyme announced the appointment of Jerald Korn as Chief Operating Officer, a strategic move to enhance their executive team. The company also reported that the first patient has been dosed in the Phase 3 portion of the SYMPHONY-1 study, evaluating tazemetostat in combination with R² for relapsed or refractory follicular lymphoma. This milestone is crucial for advancing their clinical development program. The Phase 3 study follows a successful Phase 1b safety run-in, supporting the ongoing commitment to innovative cancer therapies.